Here he became the associate professor of clinical medicine and an associate attending physician. Dry. Mammies gained his U. S. Citizenship in 1991. Dry. Mammies had a thriving practice (Mammies, M. D. , 2009). He also suffered from post Traumatic Stress Disorder from a childhood that was shadowed by his parents horrific experiences during the Holocaust. Dry. Ammine’s life eventually was consumed by his drinking. He was on the edge of losing everything when he began to research treatments that may lead to a cure. Against medical advice, he began to administer himself low doses of Faceable.
He immediately saw a change in his cravings. He no longer had to continue to drink if he started and no longer had the overwhelming urge to rink in general. He slowly increased the dose of Faceable over the next few months until the addiction seemed to be cured. Today Dry. Mammies devotes his efforts to the treatment of addiction; he now lives in both New York and Paris. To date he has ended his addiction (Mammies, 2009). Dry. Mammies was able to use Faceable to end his addiction to alcohol because Faceable adjusts the neurotransmitters and prevents alcoholics from craving alcohol.
How Faceable Works Addiction begins in the neurotransmitters of the brain. When a person drinks low doses of alcohol, it activates gamma-amino butyric acid (GAB) receptors ND stimulates the areas of the brain devoted to thinking, pleasure seeking, and relaxing. High doses of alcohol stimulate the receptors for glutamate, thereby disturbing our learning and memory, as occurs in blackouts (Mammies, 2009). The functions and characteristics associated with neurotransmitters and receptors determine how we respond physically, emotionally, and mentally to different substances (Mammies, 2009).
Thus, an imbalanced neurotransmitters is highly subject to loss of control. The second factor that goes hand and hand with GAB receptors is gamma- hydroxylation (CHUB). The nature of the role of endogenous CHUB in the body is somewhat of a mystery, but it is thought Gob’s sedative-hypnotic effects are involved in the body’s ability to relax and recover from stress. It is thought that a GHB deficiency may underline substance dependence through a GAB medicated dystrophy syndrome. A biological deficit of GHB would thus be experienced as a loss of the sedative effect, leading to anxiety, muscular tension, insomnia, and depression.
Alcohol would then serve as a replacement for the GHB when someone is in one of these uncomfortable states. Dry. Mammies believes that his research shows that Faceable bridges the gap between the GHB deficit and the GAB receptor, thereby suppressing the urge to have a drink (Mammies, 2009). In a 2003 article in Synapse, a leading neurology journal, researchers reported that Faceable reduces the dopamine release in animal studies. This report demonstrates the ability Of Faceable to modulate dopamine (Mammies, 2009). Dopamine is another neurotransmitter associated with addiction (Mammies, 2009).
The side effects of Faceable are minimal compared to similar medications to treat alcohol dependence. Side Effects The only two notable side effects of high-dose Faceable are somnolence and muscular weakness. Both only last for a day or two and are easily reversible by reducing the Faceable dose (Mammies, 2009). The side effects are minimal compared to similar medications, most highly addictive, that only reduce cravings; as opposed to Faceable that suppresses cravings. It is also important to note that Faceable has been used for decades in the treatment of seizures; Faceable has no addictive traits associated with it (Mammies, 2009).
Case Reports The three case studies included here are a baseline for determining of the effectiveness of Faceable. The first case report is a self-case report of Dry. Mammies that documents the first case in medical literature of the complete suppression of alcoholism; the second case report will highlight Backbone’s dose-dependent suppression of alcoholism in a person who has not shown any improvement through the use of alternative treatments. The third case report is especially interesting as it shows the treatment of alcoholism in a person who suffers from paranoid schizophrenic episodes (Mammies, 2009).
Case Report 1 Dry. Ammine’s self-prescribed high dose oral Faceable starting at MGM/day, tit MGM increases every third day and an (optional) additional 20-40 MGM/ day for cravings. The results were the cravings became easier to combat. After reaching the craving-suppression dose of 270 MGM/day (3. 6 MGM/keg) after five weeks, Dry. Mammies became and has remained free of alcohol dependence symptoms effortlessly for nine consecutive months. His anxiety is controlled and somnolence disappeared with a dosage reduction to 120 MGM/day in the second nine month period (Mammies, 2005).
Case Report 2 To further test whether the Faceable-induced suppression of motivation to ensure alcohol in animals could be transposed to humans the following study was preformed: A patient who had neither tolerated nor benefited from other alcohol treatment modalities was put on trial with Faceable on a dosage up to 140 MGM/day. The result was the patient reported dramatic reduction in cravings for, and preoccupation with, alcohol. Conclusion; high- dose Faceable therapy was associated with complete and prolonged suppression of symptoms and consequences of alcohol dependence (Buckram, 2007).
Case Report 3 A 49 year old male was admitted to the Division of Psychiatry at the University f Calling, Italy. He had been drinking approximately AL of wine per day for the past 20 years. He had been admitted to several hospitals over the years and diagnosed with alcohol dependence and paranoid schizophrenia. He had been treated with several different medications over the years, to no avail. Upon admission to the university of Calling in July of 2005, it was proposed to try Faceable. Starting with OMG of Faceable, 3 times a day; the dose was slowly increased to MGM, 3 times a day.
Along with marked improvement in the patient’s overall mental status, he remained alcohol free over a 48 week period. It is important to note that he was inpatient for only 6 of the 48 weeks, which shows his ability to remain alcohol free in a real-world situation, as opposed to a controlled environment. (Faceable suppresses alcohol, 2007). The Next Step for Faceable During this exploration of the drug Faceable for alcoholism, we have narrowed the results down to a minimum of reducing alcohol dependence and a perfect outcome of total suppression of alcohol dependence.
One of the problems researchers face right now is the pharmaceutical companies have no motivation to do research on a generic drug that has no potential for heir financial gain (Mammies, 2009). No medication works effectively for everyone, and Faceable is no exception. The real world numbers are that if of alcohol dependent people do not respond to Faceable, that would still leave over ninety-thousand people who could be cured. The general research shows that Faceable needs more research and FDA approval as a treatment for alcoholism if the research confirms the early findings.
Individuals who are interested in more reading material on this subject might read Dry. Ammine’s continued research in the book Heal thyself: A Doctor at the Peak of His Medical Career, Destroyed by Alcohol, and the Personal Miracle that Brought Him Back, which gives additional information and case report updates (Mammies & Hawaiian, 2010). The reality is that the skeptic in many of us would like to see more case studies done by third party organizations. However, the reality is that, without private funding (which can promote bias) the fact remains that there is no financial gain for unbiased third parties to invest in.
As a human being, my hope would be that pharmaceutical companies would research this possible cure for a disease that has plagued odder, and ancient, society for thousands of years. Unfortunately, that is not how our present system works. As for Backbone’s future; it may be a cure for alcoholism that is never properly researched in independent studies, not because there is not a need for continued research, but because of the return on investment. References (2007). Faceable suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report.
Journal of clinical psychophysiology, 27(3), 319-320. This is the third case report in The end of My Addiction”. This has an interesting twist of complete alcohol oppression combined with keeping a paranoid schizophrenic mental illness under control (“Faceable suppresses alcohol,” 2007). Gigabit, Marks, Tolerated. (2007). Faceable suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependence patient: a case report. Journal of Clinical Psychophysiology, 27(3).
The (2007) article “Faceable suppresses alcohol intake and craving for alcohol in schizophrenic alcohol-dependent patient: a case report” shows the fact that Faceable can be used with underlying mental illness to suppress alcohol cravings. This is an interesting study as most alcoholics have an underlying mental illness (Gigabit, Marks, Tolerated, 2007). Mammies. (2005). Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose Faceable: a self-case report of a physician. Alcohol and Alcoholism, 40(2), 147-150.
In the (2005) article “Complete and prolonged suppression Of symptoms and consequences of alcohol-dependence using high-dose Faceable: Mammies reveals his self administration of the drug Faceable. He explains the pros and cons of using high dose Faceable. The article explains the prolonged oppression afforded by Faceable (Mammies, 2005). Arranges, M. D. , O. (2009). The end of my addiction. (First De. ). New York: Sarah Coercion Books, Affair, Straus and Group. Olivier Mammies, M. D. (2009) book, “The End of My Addiction” centers on Dry.